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Abstract
The complexity of the clinical management of neuroendocrine neoplasia (NEN) is 
exacerbated by limitations in imaging modalities and a paucity of clinically useful 
biomarkers. Limitations in currently available imaging modalities reflect difficulties 
in measuring an intrinsically indolent disease, resolution inadequacies and inter-/
intra-facility device variability and that RECIST (Response Evaluation Criteria in Solid 
Tumors) criteria are not optimal for NEN. Limitations of currently used biomarkers 
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are that they are secretory biomarkers (chromogranin A, serotonin, neuron-specific 
enolase and pancreastatin); monoanalyte measurements; and lack sensitivity, 
specificity and predictive capacity. None of them meet the NIH metrics for clinical 
usage. A multinational, multidisciplinary Delphi consensus meeting of NEN experts 
(n = 33) assessed current imaging strategies and biomarkers in NEN management. 
Consensus (>75%) was achieved for 78% of the 142 questions. The panel concluded 
that morphological imaging has a diagnostic value. However, both imaging and current 
single-analyte biomarkers exhibit substantial limitations in measuring the disease status 
and predicting the therapeutic efficacy. RECIST remains suboptimal as a metric. A critical 
unmet need is the development of a clinico-biological tool to provide enhanced 
information regarding precise disease status and treatment response. The group 
considered that circulating RNA was better than current general NEN biomarkers and 
preliminary clinical data were considered promising. It was resolved that circulating 
multianalyte mRNA (NETest) had clinical utility in both diagnosis and monitoring disease 
status and therapeutic efficacy. Overall, it was concluded that a combination of tumor 
spatial and functional imaging with circulating transcripts (mRNA) would represent the 
future strategy for real-time monitoring of disease progress and therapeutic efficacy.
 f imaging
 f mRNA
 f MRI
 f multianalyte
 f NETest
 f neuroendocrine tumor
 f PET
 f RECIST
 f somatostatin
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Introduction
The management of neuroendocrine neoplasms (NENs, 
also called ‘NETs’) remains clinically challenging despite 
advances in classification systems (1), inauguration of 
novel therapies and innovations in imaging and the 
introduction of multidisciplinary management strategies 
(2). In particular, the management of NEN reflects diverse 
approaches often based on empiric pronouncements, local 
practical experience or the availability of certain therapies. 
Despite the promulgation of effective and applicable 
guidelines (e.g., WHO/ENETs classification of 2010) (3, 4) 
and their regular reassessment, a critical limitation is the 
dearth of large, randomized prospective trials. The precise 
delineation of definable strategies is further constrained 
by the tumor heterogeneity (diverse cell types, disparate 
molecular regulatory mechanisms and ill-understood 
oncogenic drivers) (5, 6). As a consequence, five-year 
survival rates diverge widely (15–95%), depending on 
the primary site, variable tumor biology, disease extent at 
diagnosis, available therapeutic options and designated 
centers of care (7, 8, 9). Therapeutic options remain 
diverse and run the full gamut from mechanistic excision 
to pharmacological intervention and the infusion of 
radioactive somatostatin analogs (10). Strategies include 
somatostatin receptor agonists, ‘targeted’ agents (mTOR 
inhibitors and VEGF antagonists), immunotherapy 
(interferon), cytotoxic chemotherapy, peptide receptor 
radionuclide therapy (PRRT), external radiation and 
interventional radiological or probe-directed ablation 
(11). In those with ‘indolent tumor behavior’, a watch-
and-wait-strategy is considered appropriate in certain 
selected cases (12). Apart from ‘early identified’ (usually 
serendipitous) appendiceal, rectal or gastric NETs, cure 
is uncommon, and overwhelmingly, the majority of 
treatment includes diverse combinations of strategies to 
delay local or metastatic disease progression (13). Given 
their relatively slow growth, continual assessment by 
imaging, biomarker levels and overall survival represents 
the fundamental basis for all management strategies. The 
need to monitor tumor responsiveness, both in clinical 
trials and in routine practice, is mandatory given the range 
of expensive, empirical and often times toxic treatment 
choices used (14).
For many non-neuroendocrine neoplasms, 
therapeutic responsiveness is assessed through imaging, 
but for NENs, this has well-described limitations (15, 
16, 17). Anatomic imaging using the Response Evaluation 
Criteria in Solid Tumors (RECIST) criteria exhibits well-
documented limitations (18, 19, 20). These include issues 
with lesion dimensionality and measurements thereof, 
effects of therapy on lesion appearance itself, difficulties 
with reproducibility and accurate delineation of metastatic 
disease, particularly extra-liver disease. The development 
of new lesions is probably the most powerful indicator of 
disease progression. Functional imaging with somatostatin 
receptor-based strategies, for example, 68Ga-SSA-PET/CT, 
has proved of considerable value (21); however, limited 
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spatial resolution (6–8 mm for PET scanners) and partial 
volume effects constrain the ability to delineate small 
lesions. As a consequence, timely, clinically reproducible 
assessments of progression remain unattainable (22, 23). 
Changes in the 68Ga-SSA tumor standardized uptake value 
(SUV) during treatment have not been a reliable measure 
for therapy monitoring (24, 25). 18FDG-PET, although 
useful prognostically, is not established as an early 
harbinger of tumor progression (26). Despite significant 
advances, current imaging strategies in NENs remain 
suboptimal (27, 28) and exhibit significant limitations. In 
particular, the identification and delineation of residual 
(and occult) disease is difficult.
Credible general biomarkers with broad clinical 
utility for gastroenteropancreatic (GEP) NENs remain 
unavailable although chromogranin A (CgA) and urinary 
5-hydroxyindoleacetic acid (5-HIAA; in serotonin-
secreting tumors) have been used in this capacity 
(29). Secretory (monoanalyte) biomarkers for specific 
tumor types (insulinoma: insulin, gastrinoma: gastrin, 
glucagonoma: glucagon and VIPoma: VIP) are effective 
serum indicators of tumor activity, but as this group of 
lesions represents a minority of NENs (<3–5%), its broad 
utility is limited. CgA is a constitutive product of the 
neuroendocrine cell secretory granule and is measurable in 
serum or plasma. It has been variably reported to correlate 
with tumor biology and mass and prognosticate survival 
(30, 31). Despite initial enthusiasm, the limitations 
of CgA have become increasingly evident. There is 
considerable discrepancy as to whether alterations in CgA 
have clinical utility in the identification of progressive 
disease. Although there has been some improvement in 
comparable unit use, there is no reference CgA standard, 
and wide variations exist in the assay measurements in 
different laboratories (30). Furthermore, the sensitivity 
of CgA ranges from 60% to 90% with a specificity <50% 
(depending on the population studied) (32). This reflects 
the CgA elevations associated with numerous non-NEN-
related conditions including renal failure, cardiac disease, 
other neoplasia and PPI administration (30).
The complexity and diversity of the biological 
behavior of a cancer or its response to therapy have 
been effectively addressed in scientific publications 
(33, 34). The limitations of secretory products to define 
the permutations of oncogenic genomic regulators are 
apparent and have led to the development of molecular 
technologies to better delineate cancer biology (35, 36). 
This biological research has identified extensive 
interfacing mechanisms that delineate GEP-NEN 
neoplastic development (37). A key unmet need is the 
identification of what constitutes the driver of neoplastic 
development (i.e., driver mutations) and whether this is 
clinically actionable i.e., targetable, and can be used as a 
predictive biomarker.
The majority of tumors (~95%) do not exhibit 
germline mutations (6, 38). Although genomic studies 
have revealed a number of sporadic genomic alterations, 
particularly in pancreatic NENs, the relationship between 
specific genes and tumor pathobiology remains unclear 
(5). Unlike the majority of cancers, activating mutations 
are infrequent if not largely unknown in GEP-NEN (5) with 
most tumors exhibiting mutations (when identified) in 
tumor suppressor genes. Although genomic studies seeking 
underlying driver mutations have proven disappointing 
(39, 40), transcriptome assessments have been useful in 
identifying and differentiating the different subtypes of 
NENs (based on origin e.g., pancreatic vs small intestinal, 
and aggressiveness e.g., non-progressive vs malignant/
metastatic) (41, 42) and have demonstrable predictive 
utility at a tissue level (43). More recently, blood-based 
assays (CTCs, miRNA and circulating mRNA) have been 
developed. The most extensively investigated biomarker 
tool is blood-based multianalyte transcript analysis (44, 45, 
46, 47, 48, 49, 50, 51, 52, 53, 54). Blood gene expression 
of tumor biomarkers closely correlates with tumor 
tissue expression levels, and analysis of relevant clusters 
captures NEN biology facilitating accurate definition of 
clinical status (37). The clinical application of such blood-
based information to the management of NEN disease has 
therefore become a subject for investigation. Likewise, the 
concept of fusing such data with functional imaging to 
provide a synergistic monitoring platform is worthy of 
consideration, especially given the current limitations in 
accurate monitoring.
Although biomarkers have been used in conjunction 
with imaging as adjuncts to inform clinical decision 
making, ‘biochemical’ responses using monoanalytes 
are often non-concordant with image-based assessments 
(10,  55). The detailed analysis of other neoplastic 
diseases has led to the recognition that evaluation of 
monoanalyte secretory products (exocytotic or secreted 
proteins) alone fails to adequately describe the diversity 
of neoplastic pathobiology (56). Thus, complex analytic 
strategies measuring diverse regulators of neoplastic 
cell biology interfaced with mathematical algorithms 
to facilitate interpretation have been developed for 
breast, lung and hematological malignancies (57, 58, 
59, 60). Therefore, a key unmet need that remains is 
the development of a clinically applicable, multianalyte 
biomarker that captures NEN behavior and can be used 
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to guide clinical management strategies. The use of such 
blood-based molecular information in combination with 
functional imaging would provide non-invasive real-time 
multidimensional information regarding tumor behavior.
Based on the need for a better understanding of the 
relationship between imaging and therapeutic assessment 
in NEN disease and the emergence of molecular-based 
biomarkers that have utility in assessing disease status, 
e.g., blood-based multianalyte transcript analysis NETest 
(37), a meeting of multidisciplinary experts in the field 
was convened in Castelldefels, Spain in March 2015. 
The goals of this forum were twofold. First, to establish 
a consensus on the state of the art of imaging and 
biomarkers in NEN, and secondly, to identify how these 
two information disciplines could be interfaced to provide 
added value in clinical decision making and therapeutic 
response assessment. This meeting represents a follow-up 
of a previous, more biomarker-focused Delphi consensus 
meeting that specifically examined the current status of 
circulating analytes in the management of GEP-NETs with 
respect to their individual metrics and clinical utility (61).
Materials and methods
Thirty-three multinational experts in the field of NEN 
disease diagnosis and management were identified 
including nuclear medicine physicians (n = 12; A  Kjaer, 
E  Krenning, D  Kwekkeboom, L  Bodei, V  Ambrosini, 
R Baum, J Cwikla, G Paganelli, S Severi, H Maecke, V Prasad, 
I  Virgolini), radiologists (n = 2: A  Sundin, K  Koopmans), 
endocrinologists (n = 2; M  Pavel, A  Grossman), 
gastroenterologists (n = 1, R  Jensen), oncologists (n = 9, 
K Oberg, M Tesselaar, M  Kulke, N  Fazio, R  Salazar, 
J Strosberg, A Walenkamp, M Cives, T Meyer (see Authors 
contributions)), pathologists (n = 1, A  Scarpa), basic 
scientists (n = 3, M Kidd, I Drozdov, T Korse) and surgeons 
(n = 3: M Falconi, A Frilling, I Modlin). The Delphi method 
(62) was used to achieve consensus on 142 questions, using 
a 75% agreement level as the basis for achieving consensus 
(61). Questions were categorized into four major groups 
(therapeutic management, imaging, molecular status of 
NETs and biomarkers). The first iteration of the statements 
to be discussed was developed by a core group (KO, EK, LB, 
IMM) and distributed to all participants eight weeks before 
the conference. This first round of electronic assessment 
was undertaken to eliminate or redefine inconsistencies 
or ambiguous statements (61). After integration of the 
primary assessment comments from all participants, 
this second list (revised) of statements/questions 
(yes  or  no  responses) was electronically distributed one 
month ahead of the consensus meeting. All participants 
provided answers to this interrogatory. The collated results 
of the entire group responses were made available to all 
participants at the initiation of the meeting. The meeting 
format comprised two co-moderators for each discussion 
session. Any question with less than 75% prior agreement 
(either consensus: yes or consensus: no) was then reviewed 
and discussed by the entire panel and re-voted on. Voting 
was anonymous (electronic touch pad) with re-wording of 
ambiguous, controversial or non-consensus statements as 
proposed by participants with the objective of attaining 
a 75% agreement threshold (61). Up to five re-iterations 
of a proposal were undertaken before considering an 
issue resolved. Resolution was achieved in 78%. Not all 
questions (22%) resulted in a consensus.
Results
A total of 142 questions and sub-questions were posed. The 
first round of electronic consensus was achieved before 
the March 2015 meeting in 69 (48.5%). At the meeting, 
after statement/question reformulation and repeat voting, 
final consensus was achieved on 111 (78%). The full lists 
of statements and voting results are documented in the 
Supplementary Results, see section on supplementary 
data given at the end of this article. Three participants 
(ID, HM and DK) were unable to attend the meeting 
and participate in the final round of voting. The final 
consensus therefore includes input from these members 
at rounds 1 and 2 but not round 3.
Therapeutic management
Consensus was achieved on 30 questions (47%) before 
the meeting. A further 16 (total of 72%) met consensus 
after discussion and re-voting. The panelists agreed that 
optimal management strategies required assessment of 
information based on histology, grade and stage, specific 
and non-specific symptoms, as well as knowledge regarding 
the patient’s overall condition. However, they also 
decided that clinical knowledge alone was inadequate for 
predicting whether a NEN would be progressive or exhibit 
a stable disease. Although a wait-and-see strategy was 
considered an acceptable management strategy, there was 
full concurrence that current diagnostic parameters were 
neither of adequate sensitivity nor specificity for defining 
progress. Moreover, currently available randomized 
controlled trial (RCT) data were considered insufficient 
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to accurately delineate the optimal therapeutic sequence 
strategy in NEN disease. Overall, the group concluded that 
there was a paucity of rigorous data available to facilitate 
objective, clinical decision making.
With respect to imaging, current standard diagnostic 
parameters are neither sensitive nor specific enough to 
define progress. Additional predictors of the individual 
course of disease are therefore required to identify 
individuals in whom early treatment may be of benefit. 
This would include additional imaging parameters. 
Limitations in the assessment of therapeutic responses 
with current imaging have a negative impact on patient 
management. Limitations in the discriminant index 
of both anatomic and functional imaging diminished 
the accuracy of assessment of therapeutic response. 
Somatostatin receptor (SSR) density was considered a 
relevant parameter but knowing the liver tumor load 
and pretreatment growth rate were considered important 
predictors of disease course. It was agreed that additional 
predictors of the individual course of a specific tumor are 
required to define those in whom early treatment may be 
of benefit. Biomarkers including but not limited to tissue 
gene signatures, circulating genetic information and 
mutational events were considered critical requirements 
for such a strategy.
The thresholds and cutoffs for defining Ki67 were 
considered problematic for defining when chemotherapy 
should be considered. No consensus could be reached upon 
the precise applicable cutoff. Ki67 was not considered a 
relevant parameter for predicting SSA response. Surgery 
was considered the only curative treatment, and a 
blood signature that could predict disease relapse after 
R0/R1 (primary or liver) resection was agreed upon as an 
important requirement. It was identified that selective 
internal radiation therapy (SIRT), radio frequency 
ablation (RFA) and trans-arterial (chemo-) embolization 
(TACE/TAE) were all effective in metastatic liver disease, 
though individual modalities differed in efficacy based 
upon patient selection and disease status (63). Individual 
interventions were noted to have adverse events although 
lack of comparable data prevented rigorous comparison 
(63). No consensus was reached regarding associations 
with adverse events. The use of somatostatin analogs 
(SSAs) should not only be limited to midgut and pan-
creatic NENs with Ki67 <10%. No consensus, however, 
could be reached as to whether SSAs were effective early 
in the disease course to prevent disease progression. 
Likewise, it was not accepted that there was evidence 
that above-label doses should be used in non-functioning 
progressive disease. There  were also no sufficient data 
to support the use of SSAs as anti-proliferative agents in 
patients with significant metastatic burden, e.g., >50% 
neuroendocrine tumor liver metastases (NELM) and/or 
extra-hepatic metastases. The panel was unsure whether 
everolimus had a role in non-pancreatic NEN disease 
(it should be noted that this meeting occurred before the 
publication of the Radiant-4 study (64)). Controversy 
was also apparent regarding the initial therapeutic use of 
chemotherapy. The group was of the opinion that PRRT 
might warrant consideration at an earlier time point 
in the therapeutic strategy for management of NETs 
(it should be noted that this meeting occurred before the 
availability of the NETTER-1 study results (65)). It was, 
however, deemed appropriate to consider the use of PRRT 
before other targeted therapies. Overall, a substantial lack 
of consensus (~28%) was evident for GEP-NEN therapeutic 
management. This likely reflects the individualized, 
empiric-based approaches and the divergent views of 
European and US experts.
Imaging
Consensus was achieved in 72% of questions (Fig.  1). 
There was agreement that CT or MRI should be used in 
conjunction with functional imaging. 68Ga-SSA-PET/
CT was preferred to 111In-pentetreotide scintigraphy for 
functional imaging. 68Ga-SSA-PET/CT was considered the 
preferred approach compared with 18F-DOPA imaging 
for pancreatic and small intestinal NEN diagnosis. 
18F-FDG-PET/CT was considered useful for differentiating 
high- from low-grade tumors, which might have future 
implications for staging. The technique, however, has 
prognostic implications although this requires validation 
in larger series. No consensus, however, was reached 
regarding combining 18F-FDG- and 68Ga-SSA-PET/CT or 
the timing of imaging for use of each of these modalities 
in a diagnostic setting.
Imaging was considered the best current modality 
for measuring treatment efficacy, but no consensus was 
achieved regarding the optimal strategy, PET/CT or CT or 
MRI. It was agreed that RECIST criteria were not appropriate 
for defining the therapeutic responses in NETs at least 
for biological therapy, and furthermore, inclusion of 
morphologic parameters, e.g., attenuation measurements, 
were not considered useful. No consensus was reached 
regarding whether ‘cold’ analogs e.g.,  Sandostatin or 
lanreotide (non-radioactive without bound isotopes) 
should be discontinued before somatostatin receptor 
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imaging (SRI). Overall, the heterogeneity in SSR expression 
was considered a potential sensitivity limitation to 
this approach because current ligands are SSR2/5 avid. 
Similarly, the SUVmax was also not considered an entirely 
reliable parameter for assessing patient management 
based on current ligand–receptor affinities (66). Based 
on currently available studies, different 68Ga-DOTA-SSA 
peptides (DOTA-TOC, DOTA-NOC and DOTA-TATE) were 
individually as effective in their diagnostic accuracy. 
All of them were considered to have clinical utility in 
determining clinical management.
Overall, imaging was considered more sensitive than 
existing biomarkers for detecting the disease. The group 
concurred that more effective circulating biomarkers 
would be useful adjuncts for assessing treatment. It 
was agreed that current biomarkers such as CgA do not 
correlate with imaging, particularly 68Ga-DOTA-SSA and 
18F-FDG imaging. No consensus could be reached for 
the relationship between CT or MRI and CgA. Overall, 
the panel agreed that integration of a clinically relevant, 
biologically effective biomarker strategy into response 
criteria was required to improve NEN therapy monitoring.
Molecular status of NETs
Consensus was achieved in majority of questions 
(95%). Metabolic pathways were agreed to be poorly 
characterized. The PI3K/mTOR pathway was not 
considered to be the principal growth regulatory pathway 
in NENs. It is as yet unclear what constitutes the precise 
mechanistic basis of the critical growth regulatory 
pathways of neuroendocrine tumor cells. Despite the 
proposal of numerous putative targetable pathways, 
current agents are not generally accepted as being of 
robust clinical utility (67). Alternative pathways remain 
to be defined. Mutations in the mTOR pathway were 
noted to occur in <15% of pancreatic NENs, and the 
objective response rate for everolimus (mTOR pathway 
inhibitor) is ~10% with disease stabilization in ~75% (68). 
The discrepancy between mutation rate and therapeutic 
efficacy is currently difficult to reconcile. Selective 
PI3K inhibitors were considered useful for overcoming 
everolimus resistance although the mechanisms of 
resistance remain to be defined. Mutations in the ATRX/
DAXX pathways were not considered major indicators of 
clinical outcome, and it was agreed that they should not 
be routinely assessed in pancreatic NENs. In patients with 
multiple endocrine neoplasia type I (MEN1) syndrome 
(germline MEN-1 mutation), the type of menin mutation 
was not considered to be of prognostic significance. 
Likewise, alterations in methylation patterns were not 
considered clinically useful, whereas O6-methylguanine 
DNA transferase deficiency was regarded as not significant 
in influencing the choice of therapy. Irrespective of the 
Figure 1
Clinical utility of imaging overview (Section B). Imaging for diagnosis (left) was considered effective (71% positive); 68Ga-DOTA-SSA PET/CT was 
considered more useful than either 111In-pentetreotide scintigraphy (100%) or 18F-DOPA-PET/CT (89%) for diagnosis of well-differentiated NENs. 
18F-DOPA-PET/CT was agreed to accurately differentiate (88%) low- from high-grade tumors. Imaging in therapeutic assessment (right) was overall 
considered suboptimal (36%). No consensus (gray) could be reached regarding the utility of either CT/MRI (40%) or PET-CT (46%) in the assessment of 
therapy. A combination of CT/MRI and functional imaging were considered useful (84%). There was a negative assessment of current methodologies 
including RECIST criteria (82%) and Hounsfield Units (Choi criteria) (76%). 68Ga = 68Ga-DOTA-SSA PET/CT; 111In = 111In-pentetreotide scintigraphy; 
18F = 18F-DOPA-PET/CT; HU = Hounsfield Units.
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individual molecular abnormality described, cell line 
models were considered unreliable for identifying and 
confirming the utility of any targeted agent.
No consensus could be reached regarding the role of 
VEGF expression and tumor aggressiveness. It was agreed 
that immunohistochemistry for SSR was not needed to 
define a treatment strategy, but immunohistochemistry 
(IHC) e.g., CDX2 and PAX6 was recommended when a 
primary site was unknown (CUP). Gene profiling, in this 
setting (CUP), however, was not clinically recommended. 
Overall, it remained unclear how molecular alterations, 
particularly at a DNA level, could potentially improve 
clinical management strategies. It was concluded that 
molecular alterations as currently defined did not have a 
current role in NEN treatment, but the panel did support 
continued investigation in these areas to further define 
the molecular basis of NEN disease.
Biomarkers
A consensus was reached in 89% of questions (Fig.  2). 
It was agreed that despite the paucity of DNA-related 
clinically actionable biomarkers, genomics technology 
had significant potential for identifying novel tissue 
biomarkers. The conclusion, however, was that at present, 
insufficient specific mutations and treatment-targetable 
mutations had been identified. As such, circulating DNA 
was therefore not considered a viable option for the 
development of a biomarker.
In general, circulating tumor cells (CTCs) were agreed 
not to be reliable, sensitive or specific for the detection 
(88% no) and diagnosis (92% no) of NENs. Furthermore, 
once tumors were diagnosed, CTCs were considered not 
to correlate with grade (77% no) or to have clinical utility 
as either a prognostic (85% no) or predictive biomarker 
(77% no). No consensus was achieved relating the utility 
of CTCs as an indicator of tumor burden. Although 
miRNA was considered interesting and potentially 
useful as a circulating biomarker, the group agreed that 
current technology was not adequately robust to support 
its clinical usage. Metabolomics was also considered 
of positive interest (83% yes) as was the identification of 
novel blood GEP-NEN biomarkers. The consideration of 
metabolomic assessment in urine was not supported (83% 
no). Tumor transcriptomes and mRNA studies were agreed 
to be useful for identifying tissue biomarkers and are more 
sensitive than standard biomarkers. Circulating mRNA 
assays were agreed to be worthy of further investigation 
given their potential clinical utility.
Discussion
The Delphi method, originally developed by the RAND 
Corporation (62), has been used extensively to develop 
consensus in health care. We have previously assessed 
its utility in similar clinical decision-making settings 
(61, 69). In this meeting, a substantial overall consensus 
(~80%) was achieved with 31 questions (~20%) ultimately 
unresolved (no consensus achieved). A consensus level 
of 75% was used as clear evidence of a majority opinion. 
Voting was anonymized (electronic) and followed by 
discussion when there was no consensus. The actual 
numbers of participants who completed all three rounds 
(n = 30, 91% inclusion) is similar to other Delphi-based 
studies for NENs and met the acceptability criteria for 
validity (69, 70).
Therapeutic management and imaging achieved the 
lowest consensus (72%) compared with molecular biology 
and biomarkers (88–95%). This likely reflects two issues. 
First, individual approaches to management (despite 
a focus on multidisciplinary methods) and secondly, 
differential access to imaging (68Ga-DOTA-SSA PET/CT 
is currently not generally available in the United States). 
There was a full consensus that surgery was potentially 
curative. Similarly, there was broad consensus of the 
utility of 68Ga-DOTA-SSA PET/CT both in establishing 
Figure 2
Biomarker assessment (Section D). Current monoanalyte blood 
biomarkers including CgA, serotonin and pancreastatin were considered 
inadequate overall (80%). The utility for individual strategies was 
assessed as negative for CTCs (70%) and positive, in ascending order, 
for miRNA (67%), metabolomics (75%) and circulating mRNA (80%).
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a diagnosis and having a role in staging, predicting 
response to PRRT and determining prognosis. There are a 
number of different national and societal neuroendocrine 
guidelines that variably evaluate the usage of biomarkers 
and imaging (North American – NANETs, National 
Comprehensive Cancer Network – NCCN, Canadian 
NETs and the European Neuroendocrine Tumor Society – 
ENETs (14, 71, 72, 73, 74, 75)). Each broadly supports 
the points defined in this Delphi consensus, but neither 
specifically addresses the interface between imaging and 
biomarkers nor the best strategy to integrate anatomical 
and functional imaging with circulating molecular 
information. In particular, the current consensus meeting 
evaluated not only the utility of the different strategies 
(imaging and biomarkers) but also how such modalities 
could be interfaced to provide a real-time assessment of 
the biological evolution of a neuroendocrine neoplasm. 
It was widely agreed that current approaches (RECIST) 
for assessing therapeutic responses were inadequate. In 
particular, clinical knowledge was considered insufficient 
for early and accurate predictions of progressive or stable 
disease. Moreover, it was agreed that a clinically actionable, 
biologically relevant biomarker should be included in 
treatment response assessments. This is consistent with 
the agreement reached in the previous Delphi consensus 
meeting (2014) that was designed to specifically address 
biomarker metrics and clinical utility (61).
Although biomarkers such as CgA are currently used in 
conjunction with imaging as adjuncts for clinical decision 
making (Fig. 3), significant refinements are required (61). 
In particular, implementations of more informative 
molecular tools such as multianalyte biomarkers are 
needed. Dynamic characterization of tumor behavior 
based on blood-derived genomic information is likely to 
be of considerable clinical utility, especially if used as an 
adjunct to both spatial and functional imaging. This is 
underscored by the lack of utility and clinical effectiveness 
of solely secretory biomarkers. For example, CgA does not 
correlate with imaging, particularly 68Ga-DOTA-SSA and 
18F-FDG imaging, whereas CgA biochemical ‘responses’ to 
therapy are also typically non-concordant with imaging 
(61). Indeed, a number of national and societal guidelines 
adjudge CgA to be ‘controversial’ in clinical decision 
making (14, 71).
Imaging alone, however, also has its limitations. 
The panel agreed that current strategies, although useful 
in diagnosis, were unlikely to be improved in NENs in 
the near future. For example, measurements of changes 
Figure 3
Proposed strategy for assessing the therapeutic efficacy. An integration of functional imaging and biomarker measurement including circulating tumor 
mRNA will provide combinatorial information on a real-time basis of disease status. The combination of individual imaging strategies will quantify 
tumor location/extent and in addition delineate somatostatin receptor expression (SRI – typically 68Ga-DOTA-SSA PET/CT) and tumor metabolism 
(18F-FDG-PET/CT). Circulating mRNA will measure tumor biological activity and identify treatment response.
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in Hounsfield Units, proposed in the Choi criteria for 
measuring GIST treatment responses (15), may not 
be useful in GEP-NENs. Although suitable for a rough 
estimate, SUVmax determined by 
68Ga-SSA-PET/CT, was 
also not considered to be ideal because SSR heterogeneity 
in individual tumors is a problematic factor for sensitive 
assessment of treatment response. Moreover, the 
differences in intrinsic variabilities in SUVmax in separate 
PET/CT scanners at different institutions were a limitation 
for image-based assessment and patient follow-up (54). 
Changes in tumor SUVmax during PRRT do not always 
correlate with the outcome (25, 76) and in tumors with 
SUVmax >20–25, SUV does not linearly correlate with 
SSR expression (77). Other imaging biomarkers, such as 
activated glucose metabolisms (18F-FDG-PET) are now 
being re-evaluated, and optimism exists regarding their 
future prognostic role in NEN management although 
prospective validation is required (17). Although 
guidelines have, in general, supported serial comparisons 
between images to evaluate changes in tumors (14, 71), 
a RECIST approach has not been recommended in 
neuroendocrine tumor disease. This is consistent with 
the opinions of the experts at this Delphi consensus who 
opined that the current configuration of RECIST criteria 
was suboptimal for application to NET disease assessment. 
Additional parameters that potentially could be included 
to improve imaging, however, remained unresolved. 
The overall consensus was that adjunct biomarker tools 
should be developed to provide synergistic information 
with imaging as a means to facilitate the assessment 
of therapy. It was agreed that a better understanding 
of tumor biology would unquestionably expedite the 
development of an appropriate therapeutic biomarker(s). 
The determination of therapeutic strategy by 
identification of a biomarker is limited to the assessment 
of SSR expression before the use of PRRT. The use of 
current pharmacological therapy is critically limited by 
the absence of pretreatment biomarker identification and 
the lack of tools to accurately define efficacy.
Molecular strategies have thus far typically focused 
on DNA alterations but are clinically non-informative. 
Mutations in MEN-1, the predominant sporadic NEN 
mutation (pancreatic NENs), are not associated with 
differences in SSR expression and detection by SRI (78, 79). 
Moreover, the clinical usefulness of alterations in ATRX, 
DAXX, mTOR signaling (40) and YY1 (80) (all principally 
identified as sporadic mutations in pancreatic NENs) 
remain to be proven. Furthermore, the prognostic and 
predictive utility of the recently identified IMPK mutation 
in a single small bowel carcinoid family (81) remains to be 
defined. In addition, the clinical usefulness of chemical-
based DNA modifications e.g., methylation, requires 
elucidation. Alternatives to DNA-based molecular strategies 
included assessment of CTCs, miRNA, metabolomics and 
transcriptome-based approaches. The panel considered 
miRNA to have potential utility. Data indicated that 
tissue-derived microRNAs are detectable in patient serum 
samples and may be altered by somatostatin analogs (82). 
Similarly, metabolomics investigations were considered 
of interest because functional and non-functional tumors 
are readily separated (R2 = 0.98) (83). More clinical data 
are necessary to further assess the clinical utility. With 
respect to CTCs, the consensus was that this parameter 
remained problematic at the present time. Although 
there is some literature to support CTCs (84, 85), all 
represent a single-center study and hence enthusiasm 
was diminished. Concerns were also raised with regard to 
technological aspects of the measurement. Analysis of the 
results demonstrates that the clinical sensitivity (number 
of patients with detectable CTCs) is low, 33% in the first 
study and 49% in the second study. Such low numbers 
may reflect variable EpCAM expression used for tumor 
cell capture. Irrespective of technical issues, it remains 
difficult to reconcile the utility of a test that is based on 
the absence or presence of 1 circulating tumor cell. This 
opinion directly recapitulated the opinion expressed 
at the biomarker-focused Delphic consensus meeting 
(2014) where a separate group of international experts 
expressed a similar lack of enthusiasm for the clinical 
utility of circulating tumor cell technology (61). None of 
these parameters (CTC, miRNA and metabolomics) are 
currently clinically recommended in guidelines. Overall, 
blood-based multianalyte transcript analysis (44, 45), 
with a clinical sensitivity >95% was considered, by the 
group, to be more sensitive than standard biomarkers and 
of potential clinical utility. This is concordant with the 
consensus from the previous Delphi panel (2014) which 
evaluated the efficacy, metrics and clinical utility of current 
NET biomarkers (61). Its precise application to guiding 
therapy was considered to require further evaluation. 
Current preliminary data (6, 46) were, however, noted 
to have specifically addressed clinical utility in sporadic, 
well-differentiated GEP-NETs. A role in familial NETs 
(including germline MEN-1 and VHL mutations) is 
currently under evaluation. The efficacy of a molecular 
tool capable of detecting germline disease evolution 
over time is of particular clinical relevance given the low 
accuracy of current biomarkers and the limitations of 
imagery (sensitivity and radiation exposure) as a life-long 
monitoring tool (86). The areas of efficacy were identified 
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as assessment of the effectiveness of curative surgery, 
assessment of the efficacy of SSA therapy, prediction of 
disease stability/progression and identification of response 
to PRRT. The signature was decreased by surgery and values 
corresponded to the completeness of tumor removal (49). 
In addition, elevated levels after R0 resection predicted 
subsequent disease recurrence. In a different study, 
elevated transcript levels were prognostic of SSA failure/
disease progression (51). Of note was the observation 
that alterations in transcript levels occurred significantly 
earlier than RECIST- or SRI-based measures of disease 
progression (51). Finally, levels were prognostic for PRRT 
efficacy and could be used to evaluate therapy, correlating 
with image-based assessments (53). The observation 
that NEN gene blood levels correlated with 68Ga-DOTA-
SSA PET/CT imaging and could define disease status was 
considered worthy of further clinical study (52). In the 
latter study, a quotient including specific genes and the 
SUVmax accurately predicted clinical status. Thus, stable 
disease could be differentiated from progression using 
a time point amalgam of a single image/blood sample. 
The group considered that the combination of imaging 
and circulating blood biomarkers offered a potential 
for fusing these two functional modalities of treatment 
assessment into a clinical index of disease status. This 
novel consideration had not been previously evaluated 
at the initial Delphi analysis (2014), which developed a 
biomarker-centric analysis of disease management. The 
larger and more diverse international cohort of experts 
that comprised the current Delphi group was designed to 
assess the effectiveness and facility of the integration of 
validated imaging strategies as a combinatorial clinical 
assessment tool with biomarkers.
In conclusion, there was consensus among a large 
(n = 33) group of NEN disease experts from diverse medical 
and scientific disciplines and countries that current 
Figure 4
Conceptual proposal for the evaluation of therapeutic efficacy. This provides an integration of functional imaging and tumor molecular biology using 
circulating multianalyte assays with algorithm analyses (MAAA)s, mRNA or miRNA. Disease progress can be delineated using a combination of functional 
imaging modalities quantifying somatostatin receptor expression (SSR) by 68Ga-DOTA-SSA PET/CT and tumor metabolism using either 18F-DOPA PET/CT 
(in well-differentiated tumors) or 18F-FDG (mainly in undifferentiated forms or to assess tumor aggressiveness). The MAAA e.g., circulating mRNA, 
provides an accurate reflection of tumor activity. Overall, the combination of functional imaging (68Ga-SSA and 18F-FDG-PET/CT) and circulating mRNA 
could, in the future, help to delineate treatment efficacy.
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imaging and circulating biomarkers for NEN disease have 
substantial limitations for predicting disease activity and 
for measuring therapeutic efficacy. In addition, RECIST 
remains suboptimal as a metric of disease status, and 
better tools for assessment and improved techniques 
for imaging require development. These views broadly 
recapitulate published guidelines for GEP-NETs (14, 71, 
72, 73, 74, 75) while providing a more in depth and 
detailed evaluation of the strengths and weaknesses 
of the different strategies and how best they might be 
integrated to provide synergistic information of clinical 
utility. It was concluded that a critical requirement was 
the development of a multianalyte molecular tool that 
can better identify disease status and define treatment 
response. In this respect, the use of circulating RNA as a 
biomarker was confirmed to supersede the effectiveness 
of standard monoanalyte biomarkers and have potential 
clinical applicability. This assessment corroborated 
the outcome of the previous biomarker-centric Delphi 
consensus meeting (61). Current data suggest added value 
for the transcript analysis in the monitoring of diverse 
therapeutic modalities, particularly in conjunction 
with other parameters to monitor disease progression 
(Fig. 4). The NEN experts concluded that combinations 
of imaging and blood-based molecular information 
provided by transcriptome analysis could offer the most 
promising future strategy for refining and improving the 
evaluation of therapy.
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